psychedelics

News

ICER raps conduct of Lykos’ psychedelic trial for PTSD

The Institute for Clinical and Economic Review (ICER) typically focuses on the cost-effectiveness of new therapies, but in an unusual move has sharply criticised the desig

News

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

The FDA has confirmed that it will convene an advisory committee meeting on 10th June to discuss Eli Lilly’s Alzheimer’s disease candidate donanemab, after announcing a de

R&D

Psychedelic treatments on cusp of approval, but questions re...

There is a new wave of psychedelic treatment moving through clinical trials targeting mental health conditions, and they are showing strong efficacy.

News

Cosmo Feilding Mellen, Beckley Psytech’s chief executive

Beckley builds case for its psychedelic depression therapy

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d

News

Cybin bags breakthrough tag for psychedelic depression drug

It has been a busy week for psychedelic medicines developer Cybin, marked by a breakthrough designation (BTD) from the FDA for its depression therapy, new clinical data, a

News

MindMed gets FDA breakthrough tag for LSD in anxiety

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120

ICER raps conduct of Lykos’ psychedelic trial for PTSD

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

Psychedelic treatments on cusp of approval, but questions re...

Beckley builds case for its psychedelic depression therapy

Cybin bags breakthrough tag for psychedelic depression drug

MindMed gets FDA breakthrough tag for LSD in anxiety

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

psychedelics

Editor's Picks